Theratechnologies Inc.
theratech.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2024 20-F, filed Feb 26, 2025. Its latest SEC filing is a EFFECT from Nov 28, 2025.
20-F for FY2024, filed Feb 26, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Commercializes EGRIFTA SV and Trogarzo, medicines for people living with HIV.
20-F for FY2024, filed Feb 26, 2025We currently commercialize two approved products for people living with HIV, namely: EGRIFTA SV® and Trogarzo® in the United States.View ↗
EGRIFTA SV® (tesamorelin for injection) is a new formulation of EGRIFTA® which was originally approved by the FDA in November 2010 and was…View ↗
Trogarzo® (ibalizumab-uiyk) injection was approved by the FDA on March 6, 2018, and, in combination with other antiretrovirals (“ARV”), is…View ↗
Who Were Their Customers?
The company sells finished goods to customers; its sales arrangements mention distributors, government agencies and retail pharmacies.
20-F for FY2024, filed Feb 26, 2025
Did Revenues Turn Into Profits?
No. It lost $8.3M in .
20-F for FY2024, filed Feb 26, 2025
20-F for FY2024, filed Feb 26, 2025
−$8.3MView ↗
Loading...
